Somatropin (rDNA original) for injection


White lyophilized powder


4 IU (1,33 mg) and 10 IU (3,33 mg)

  • 5 vials with lyophilized powder (5 ampoules with water for injection, 5 syringes)
  • 10 vials with lyophilized powder (10 ampoules with water for injection)
  • 20 vials with lyophilized powder (without ampoules)
  • 50 vials with lyophilized powder (50 ampoules with water for injection)
PHARMACO-THERAPEUTIC GROUP Human Growth Hormone, hGH (r DNA origin). Jintropin stimulates linear growth and increases growth rate in children who lack adequate endogenous growth hormone. In adults with growth hormone deficiency, JINTROPIN reduces fat mass, increases, muscle mass and improves energy, vitality and subjective well-being. In patients suffering from severe burns, AIDS associated muscle wasting , or undergoing major operations ,JINTROPIN promotes wound healing, attenuates the protein-catabolic response and improves whole-body nitrogen condition after operation.
THERAPEUTIC INDICATIONS Growth disturbance due to insufficient secretion of growth hormone or associated with gonadal dysgenesis or Turner's syndrome which is a chromosome aberration.
Growth disturbance in prepubertal children with chronic renal insufficiency.
Replacement therapy in adults with pronounced growth hormone deficiency.
Promote wound healing and attenuate catabolic responses in severe burns, sepsis, multiple trauma, major operations, acute pancreatitis and intestinal fistula.
Topical application to promote wound healing in acute wound or chronic ulcer, such as burns, diabetic foot ulcer, chronic venous ulcer and decubital ulcer.
CONTRAINDICATIONS Jintropin should not be used when there is any evidence of activity of a tumor. Intracranial lesions must be inactive and antitumour therapy completed prior to starting therapy. Jintropin should not be used for growth promotion in children with closed epiphyses.
Address Name Phone